Greenwich Lifesciences, Inc. (GLSI) Stock Price & Analysis

Greenwich Lifesciences, Inc. (GLSI) rose 2.68% to USD 22.23 as of June 10, 2026 at 00:58 UTC, according to Nexqual real-time market data.

GLSI last closed at USD 21.65; the session ranged USD 21.4–22.56 on volume of 85,350 shares. Market capitalization is $326.30M, with a 52-week range of USD 7.78–34.1 (NCM). Source: Nexqual, June 10, 2026 at 00:58 UTC.

Key Statistics (as of June 10, 2026 at 00:58 UTC)

Technical Analysis (GLSI)

Nexqual's technical model rates GLSI "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:58 UTC.

Analyst Ratings (GLSI)

Wall Street analysts rate GLSI "Strong Buy" based on 2 analysts, with a mean price target of USD 47.5 (range USD 45–50), per Nexqual as of June 10, 2026 at 00:58 UTC.

Earnings (GLSI)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 00:58 UTC.

Financials & Fundamentals (GLSI)

Source: Nexqual, June 10, 2026 at 00:58 UTC.

Financial Health Score (GLSI)

Nexqual rates Greenwich Lifesciences, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:58 UTC.

Ownership (GLSI)

Source: Nexqual, June 10, 2026 at 00:58 UTC.

Leadership (GLSI)

Greenwich Lifesciences, Inc. is led by Snehal S. Patel (age 61), CEO, CFO & Director, per Nexqual as of June 10, 2026 at 00:58 UTC.

Major Backers & Investors (GLSI)

Notable institutional backers of Greenwich Lifesciences, Inc. include Fidelity, Russell Investments Group, Ltd., RUSSELL INVESTMENT CO-Tax-Managed U.S. Mid & Small Cap Fund, according to Nexqual as of June 10, 2026 at 00:58 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 00:58 UTC.

From Greenwich Lifesciences, Inc.'s Latest SEC 10-K Filing (filed 2026-06-01)

Key Strengths & Strategy (as disclosed to the SEC)

• In addition, we include restrictions regarding use and disclosure of our proprietary information in our contracts with third parties, and utilize customary confidentiality agreements with our employees, consultants, clinical investigators, and scientific advisors to protect our confidential information and know-how.
• We also rely on trade secrets, know-how, and continuing technological innovation to develop and maintain our proprietary position.   The term of individual patents depends upon the legal term of the patents in countries in which they are obtained.

Partnerships

• HJF may terminate the license if we do not make required payments, if we default in our performance obligations, if we do not sufficiently develop and advance GP2 towards commercialization, and for various other reasons.     In connection with the exclusive license agreement with HJF, we were the financial and corporate sponsors of the GP2 Phase IIb clinical trial.
• Patent and Trademark Office in examining and granting a patent or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date.   HJF License   Pursuant to our exclusive license agreement with HJF, we were granted exclusive worldwide rights to several U.S. and foreign patents and patent applications covering methods of using GP2.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:58 UTC. This page is informational and not investment advice.